SangKon Oh
31Patents
7h-index
22Co-inventors
69Inventor score
Filing activity: Jun 2, 2004 → Jun 6, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9102734B2 | Fusion proteins comprising antibody and HPV E6 and E7 antigens | Emerging Cross-Sectional Technologies | 39 | Active |
| US8236934B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 32 | Active |
| US9453074B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 30 | Active |
| US8728481B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 30 | Active |
| US9109011B2 | Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef | Chemistry; Metallurgy | 13 | Active |
| US8481314B2 | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1) | Emerging Cross-Sectional Technologies | 9 | Active |
| US9339556B2 | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1) | Emerging Cross-Sectional Technologies | 9 | Active |
| US9562104B2 | Anti-CD40 antibodies | Emerging Cross-Sectional Technologies | 5 | Active |
| US9315580B2 | Vaccines directed to langerhans cells | Chemistry; Metallurgy | 5 | Active |
| US7541035B2 | Immunogenic peptides for the treatment of prostate and breast cancer | Human Necessities | 2 | Expired |
| US9061066B2 | Immunoadjuvant compounds and uses thereof | Human Necessities | 2 | Active |
| US10286058B2 | Vaccines against HPV and HPV-related diseases | Chemistry; Metallurgy | 2 | Active |
| US9045542B2 | Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2) | Chemistry; Metallurgy | 1 | Active |
| US10683361B2 | Anti-CD40 antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US9567401B2 | Anti-CD40 antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US10087256B2 | Method of making an anti-CD40 antibody | Emerging Cross-Sectional Technologies | 1 | Active |
| US10980869B2 | Fusion proteins comprising an anti-CD40 antibody and cancer antigens | Emerging Cross-Sectional Technologies | 0 | Active |
| US11957734B2 | Methods and compositions for treating autoimmune and inflammatory conditions | Chemistry; Metallurgy | 0 | Active |
| US11173202B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 0 | Active |
| US11267895B2 | Nucleic acids encoding anti-CD40 antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US8043623B2 | Immunogenic peptides for the treatment of prostate and breast cancer | Human Necessities | 0 | Active |
| US10167339B2 | Antagonistic anti-OX40L antibodies and methods of their use | Chemistry; Metallurgy | 0 | Active |
| US11717567B2 | Vaccines against HPV and HPV-related diseases | Chemistry; Metallurgy | 0 | Active |
| US10279030B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 0 | Active |
| US12016915B2 | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.